share_log

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

HC Wainwright & Co.将表面肿瘤学评级下调至中性,宣布5美元的目标价格
Benzinga ·  2023/06/20 06:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Surface Oncology (NASDAQ:SURF) from Buy to Neutral and announces $5 price target.

HC Wainwright & Co. 分析师Swayampakula Ramakanth将表面肿瘤学(纳斯达克股票代码:SURF)的评级从买入下调至中性,并宣布了5美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发